物質使用障害（SUD）- 市場考察、疫学、市場予測（2034年）

主なハイライト

• 物質使用障害（SUD）とは、否定的な結果にもかかわらず、薬物の使用をコントロールできない状態を指します。症状は4つのカテゴリに分類されます。コントロール障害（欲求、やめようとする試みの失敗）、社会的問題（責任の放棄）、危険な使用（危険な状況での物質使用）、薬物の影響（耐性と離脱症状）です。
• SUDに関与する一般的な物質には、アルコール、オピオイド、覚せい剤、コカイン幻覚剤、タバコなどがあります。各物質にはその使用に伴う特有の作用やリスクがあり、過剰摂取は治療しなければ致命的となる可能性があります。
• VIVITROL（naltrexone）、SUBLOCADE（buprenorphine）などのさまざまな薬剤がSUD治療薬として承認されています。
• 2024年10月、IndiviorはFDAがSUBLOCADEの迅速導入/代替注射部位に対するPAS（Prior Approval Supplement）の優先審査を認めたと発表しました。PDUFA（Prescription Drug User Fee Act）の施行日は2025年2月7日に設定されています。
• 2023年、フランスが約4億9,400万米ドルと、欧州4ヶ国・英国の中でもっとも大きい市場規模を持っています。
• 主要7市場では、米国が2023年に約6,500万人のSUDと診断された患者数を占め、各国の中でもっとも多いです。
• 米国では、2023年にもっとも有病率の高い物質特異的症例としてタバコ使用障害が報告され、約2,600万例でした。
• 特にアルコール使用障害（AUD）に重点を置いたSUD治療薬として、現在数多くの医薬品が開発中であり、その中にはmavoglurant、EMB-001、NFL-101、TMP-301などの有望な治療薬も含まれており、予測期間（2024年～2034年）に主要7市場で上市する予定です。
• 2024年11月、PleoPharmaが大麻離脱に関する臨床試験の良好なフェーズIb結果をAmerican Academy of Addiction Psychiatry（AAAP）Annual Meetingで発表しました。
• 2024年9月、Kinnov TherapeuticsはENCP Congressに出席し、KT-110のフェーズII臨床試験の結果を発表しました。
• 開発中の新治療法の数が増加していることは、SUDの治療オプションの進歩に向けた大きな後押しを強く示しています。

市場

Imbrium Therapeutics、Kinnov Therapeutics、Alkermes、Indiviorなど、少数の主要企業が物質使用障害（SUD）の治療情勢をリードしています。国別と治療法別の市場規模の詳細を以下に示します。

• 主要7市場では、米国がもっとも高い市場シェア、すなわち2023年に60%超を占め、フランス、ドイツがこれに続きました。
• 米国は2023年に約30億米ドルの収益を計上しました。
• 欧州4ヶ国・英国の中で、2023年の市場規模がもっとも大きいのはフランスで、約4億9,000万米ドルです。
• 市場規模は、欧州4ヶ国・英国の中では英国がもっとも小さく、2023年に約2億5,000万米ドルでした。

薬物使用障害（SUD）市場の見通し

VIVITROL（naltrexone）、SUBLOCADE（naltrexoneの徐放製剤）など、オピオイド受容体を遮断し、欲求を抑えることで依存症に対処する医薬品が承認され、SUDの治療情勢は大きく前進しました。これらの薬剤は、回復を支援する上で重要な役割を果たしています。確立された治療法に加え、gabapentin + nabiloneやcyproheptadine + prazosinといった新しい薬の組み合わせは、SUD治療のさらなる改善に有望です。これらの組み合わせは、依存症に関与するさまざまな経路を標的とし、欲求を抑え、離脱症状を管理し、再発を予防することを目的としています。研究が進むにつれて、これらの新治療薬は、特に従来の薬物療法にあまり反応しなかった患者に対して、より個別化された効果的な治療オプションを提供する可能性があります。SUD治療市場は、新しい分子や併用療法が開発され、より成功する治療法への道が開かれるにつれて拡大すると予測されます。

当レポートでは、物質使用障害（SUD）の主要7市場（米国、ドイツ、スペイン、イタリア、フランス、英国、日本）について調査分析し、各地域の市場規模、現在の治療法、アンメットニーズ、新薬などの情報を提供しています。

目次

第1章 重要考察

第2章 レポートのイントロダクション

第3章 SUD市場の概要

• 主要7市場のSUDの市場シェアの分布（2023年）
• 主要7市場のSUDの市場シェアの分布（2034年）

第4章 調査手法

第5章 エグゼクティブサマリー

第6章 重要な出来事

第7章 疾患の背景と概要

• SUDの症状
• 依存症サイクルの段階
• SUDの種類
  • アルコール使用障害
  • 大麻使用障害
  • フェンシクリン使用障害
  • その他の幻覚剤使用障害
  • 吸入剤使用障害
  • オピオイド使用障害
  • 鎮静剤、催眠剤、抗不安薬使用障害
  • 覚醒剤使用障害
• 危険因子
• SUDにおける生活の質
  • 生活の質への一般的な影響
  • メンタルヘルスの合併症
  • 領域固有の調査結果
  • 生活の質の予測因子
  • 介入の必要性
• 病因
  • 遺伝的影響
  • 神経生物学的メカニズム
  • 環境要因
  • 精神疾患の併存
• SUDの診断
  • SUDにおけるバイオマーカー
  • 診断ガイドライン
  • 鑑別診断

第8章 SUDの治療と管理

• 使用される治療法の種類
  • 行動療法
  • 家族療法
  • 個人カウンセリング
  • 集団療法
• 効果的な薬物依存症治療の原則
• 治療アルゴリズム
  • 治療ガイドライン

第9章 疫学と患者人口

• 主な調査結果
• 前提条件と根拠：主要7市場
• 主要7市場のSUDの診断された患者の総数
• 主要7市場のSUDの治療された患者の総数
• 米国
• 欧州4ヶ国・英国
• 日本

第10章 ペイシェントジャーニー

第11章 上市済みの治療法

• 主な競合
• VIVITROL（naltrexone）：Alkermes
• SUBLOCADE（buprenorphine）：Indivior
• BRIXADI/BUVIDAL（buprenorphine）：Braeburn
• SELINCRO（nalmefene）：Lundbeck/Otsuka Pharmaceuticals

第12章 新治療法

• 主な競合
• IGALMI（Dexmedetomidine）：BioXcel Therapeutics
• NFL-101：NFL Biosciences
• Mavoglurant（STP7/AFQ056）：STALICLA
• EMB-001：Embera NeuroTherapeutics
• PP-01（Gabapentin + nabilone）：PleoPharma
• KT-110（Cyproheptadine + Prazosin）：Kinnov Therapeutics
• Sunobinop：Imbrium Therapeutics
• BPL-003（Mebufotenin）：Atai Life Sciences/Beckley Psytech

第13章 物質使用障害（SUD）：主要7市場の分析

• 主な調査結果
• 市場見通し
• コンジョイント分析
• 主な市場予測の前提条件
• 物質使用障害（SUD）：主要7市場の分析
  • 主要7市場のSUDの総市場規模
  • 主要7市場のSUDの市場規模：治療法別
• 米国の市場規模
  • 米国のSUDの総市場規模（2020年～2034年）
  • 米国のSUDの市場規模：治療法別（2020年～2034年）
• 欧州4ヶ国・英国の市場規模
  • 欧州4ヶ国・英国のSUDの総市場規模（2020年～2034年）
  • 欧州4ヶ国・英国のSUDの市場規模：治療法別（2020年～2034年）
• 日本の市場規模
  • 日本のSUDの総市場規模（2020年～2034年）
  • SUDの市場規模：治療法別

第14章 KOLの見解

第15章 SWOT分析

第16章 アンメットニーズ

第17章 市場参入と償還

• 米国
• 欧州
• 日本

第18章 付録

第19章 DelveInsightのサービス内容

第20章 免責事項

List of Tables

• Table 1: Summary of SUD Market and Epidemiology (2020-2034)
• Table 2: DSM- V Criteria for SUDs
• Table 3: ICD-10 guidelines for SUD
• Table 4: Principles of Drug Addiction Treatment
• Table 5: VA/DoD Clinical Practice Guideline for the Management of SUD
• Table 6: Guidelines for Identification and Management of SUD in Pregnancy
• Table 7: Treatment Recommendations for Patients With SUD
• Table 8: Total Diagnosed Prevalent Cases of SUD in 7MM in Million (2020-2034)
• Table 9: Total Treated Cases of SUD in 7MM in Million (2020-2034)
• Table 10: Total Diagnosed Prevalent Cases of SUD in the United States in Million(2020-2034)
• Table 11: Substance type-specific Cases of SUD in the United States in Million(2020-2034)
• Table 12: Total Treated Cases of SUD in the United States in million (2020-2034)
• Table 13: Total Diagnosed Prevalent Cases of SUD in EU4 and the UK in Million(2020-2034)
• Table 14: Age group-specific Cases of SUD in EU4 and the UK in Thousand (2020-2034)
• Table 15: Total Treated Cases of SUD in EU4 and the UK in Million(2020-2034)
• Table 16: Total Diagnosed Prevalent Cases of SUD in Japan in Million(2020-2034)
• Table 17: Substance type-specific Cases of SUD in Japan in Thousand (2020-2034)
• Table 18: Total Treated Cases of SUD in Japan in Million(2020-2034)
• Table 19: Key Cross (Marketed Therapies)
• Table 20: VIVITROL (naltrexone), Clinical Trial Description, 2024
• Table 21: SUBLOCADE (buprenorphine), Clinical Trial Description, 2024
• Table 22: BRIXADI (buprenorphine), Clinical Trial Description, 2024
• Table 23: SELINCRO, Clinical Trial Description, 2024
• Table 24: Key Cross (Emerging Therapies)
• Table 25: IGALMI Clinical Trial Description, 2024
• Table 26: NFL101 Clinical Trial Description, 2024
• Table 27: STP7 (mavoglurant) Clinical Trial Description, 2024
• Table 28: EMB-001: Clinical Trial Description, 2024
• Table 29: PP-01 Clinical Trial Description, 2024
• Table 30: KT-110 Clinical Trial Description, 2024
• Table 31: Sunobinop Clinical Trial Description, 2024
• Table 32: BPL-003 Clinical Trial Description, 2024
• Table 33: Key Market Forecast Assumption of SUD in the United States
• Table 34: Key Market Forecast Assumption of SUD in EU4 and the UK
• Table 35: Key Market Forecast Assumption of SUD in Japan
• Table 36: Total Market Size of SUD in the 7MM in USD Million (2020-2034)
• Table 37: Market Size of SUD by Therapies in the 7MM in USD Million (2020-2034)
• Table 38: Total Market Size of SUD in the United States in USD Million (2020-2034)
• Table 39: Market Size of SUD by Therapies in the United States in USD Million (2020-2034)
• Table 40: Total Market Size of SUD in EU4 and the UK in USD Million (2020-2034)
• Table 41: Market Size of SUD by Therapies in EU4 and the UK in USD Million (2020-2034)
• Table 42: Total Market Size of SUD in Japan in USD Million (2020-2034)
• Table 43: Market Size of SUD by Therapies in the Japan in USD Million (2020-2034)
• Table 44: Nalmefene - extent and probability of added benefit
• Table 45: SELINCRO (nalmefene) reimburesment
• Table 46: Medical service rendered (SMR)
• Table 47: Improvement of medical service rendered (ASMR)
• Table 48: Nalmefene for reducing alcohol consumption in people with alcohol dependence

List of Figures

• Figure 1: Cycle of Stigma
• Figure 2: The Three Stages of the Addiction Cycle
• Figure 3: Most Common Risk Factors
• Figure 4: Pathogenesis of SUD
• Figure 5: Circuits Dysregulated by Repeated Drug Exposure
• Figure 6: Treatment Algorithm for SUD
• Figure 7 Total Diagnosed Prevalent Cases of SUD in 7MM (2020-2034)
• Figure 8: Total Treated Cases of SUD in 7MM (2020-2034)
• Figure 9: Total Diagnosed Prevalent Cases of SUD in the United States (2020-2034)
• Figure 10: Substance type-specific Cases of SUD in the United States (2020-2034)
• Figure 11: Total Treated Cases of SUD in the United States (2020-2034)
• Figure 12: Total Diagnosed Prevalent Cases of SUD in EU4 and the UK (2020-2034)
• Figure 13: Substance type-specific Cases of SUD in EU4 and the UK (2020-2034)
• Figure 14: Total Treated Cases of SUD in EU4 and the UK (2020-2034)
• Figure 15: Total Diagnosed Prevalent Cases of SUD in Japan (2020-2034)
• Figure 16: Substance type-specific Cases of SUD in Japan (2020-2034)
• Figure 17: Total Treated Cases of SUD in Japan (2020-2034)
• Figure 18: Total Market Size of SUD in the 7MM (2020-2034)
• Figure 19: Market Size of SUD by Therapies in the 7MM (2020-2034)
• Figure 20: Total Market Size of SUD in the US (2020-2034)
• Figure 21: Market Size of SUD by Therapies in the United States (2020-2034)
• Figure 22: Total Market Size of SUD in EU4 and the UK (2020-2034)
• Figure 23: Market Size of SUD by Therapies in EU4 and the UK (2020-2034)
• Figure 24: Total Market Size of SUD in Japan (2020-2034)
• Figure 25: Market Size of SUD by Therapies in Japan (2020-2034)
• Figure 26: Unmet Needs

Key Highlights:

• Substance Use Disorder (SUD) is a condition marked by an inability to control substance use despite negative consequences. Symptoms are grouped into four categories: impaired control (cravings, failed attempts to quit), social problems (neglecting responsibilities), dangerous use (substance use in risky situations), and drug effects (tolerance and withdrawal).
• Common substances involved in SUD include alcohol, opioids, stimulants, Cocaine hallucinogens, tobacco, and others. Each substance can have unique effects and risks associated with its use, and overdose can be potentially fatal if untreated.
• Various drugs have been approved for SUD treatment, including VIVITROL (naltrexone), SUBLOCADE (buprenorphine), and others.
• In October 2024, Indivior announced that the FDA granted Priority Review for its Prior Approval Supplement (PAS) for SUBLOCADE rapid Induction/Alternative Injection Site. The Prescription Drug User Fee Act (PDUFA) action date is set for February 7, 2025.
• In 2023, France accounted for the highest market size, approximately USD 494 million, among the EU4 and the UK in 2023.
• In the 7MM, the US accounted for approximately 65 million diagnosed prevalent cases of SUD in 2023, the highest number among the countries.
• In the United States, tobacco use disorder was reported as the most prevalent substance-specific case in 2023, with approximately 26 million cases.
• Numerous drugs are currently in development for the treatment of SUD, with a particular emphasis on Alcohol Use Disorder (AUD), including promising therapies like mavoglurant, EMB-001, NFL-101, TMP-301, and others, which are set to launch in the 7MM during the forecast period (2024-2034).
• In November 2024, PleoPharma presented the positive Phase Ib results from its clinical trial on cannabis withdrawal at the American Academy of Addiction Psychiatry (AAAP) Annual Meeting.
• In September 2024, Kinnov Therapeutics was present at the ENCP Congress, where they presented the results of their Phase II clinical trials for KT-110.
• The growing number of emerging therapies in development highlights a critical push towards advancing treatment options for SUD.

Report Summary

• The report offers extensive knowledge regarding the epidemiology segments and predictions, presenting a deep understanding of the potential future growth in diagnosis rates, disease progression, and treatment guidelines. It provides comprehensive insights into these aspects, enabling a thorough assessment of the subject matter.
• Additionally, an all-inclusive account of the current management techniques and emerging therapies and the elaborative profiles of late-stage (Phase II and Phase I) and prominent therapies that would impact the current treatment landscape and result in an overall market shift has been provided in the report.
• The report also encompasses a comprehensive analysis of the Substance Use Disorder market, providing an in-depth examination of its historical and projected market size (2020-2034). It also includes the market share of therapies, detailed assumptions, and the underlying rationale for our methodology. The report also includes drug outreach coverage in the 7MM region.
• The report includes qualitative insights that provide an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, including experts from various hospitals and prominent universities, patient journey, and treatment preferences that help shape and drive the 7MM substance use disorder market.

Market

A few key players are leading the treatment landscape of Substance Use Disorder, such as Imbrium Therapeutics, Kinnov Therapeutics, Alkermes, Indivior and others. The details of the country-wise and therapy-wise market size have been provided below.

• In the 7MM, the United States accounted for the highest market share, i.e. more than 60% in 2023, followed by France and the Germany.
• The United States generated the revenue of approximately USD 3000 million in 2023.
• Among the EU4 and the UK, France accounted for highest market size in 2023 with approximately USD 490 million.
• The United Kingdom accounted for the least market size, approximately USD 250 million, among the EU4 and the UK in 2023.

Substance Use Disorder (SUD) Drug Chapters

The section dedicated to drugs in the Substance Use Disorder report provides an in-depth evaluation of late-stage pipeline drugs (Phase II) related to Substance Use Disorder. The drug chapters section provides valuable information on various aspects related to clinical trials of Substance Use Disorder, such as the pharmacological mechanisms of the drugs involved, designations, approval status, patent information, and a comprehensive analysis of the pros and cons associated with each drug. Furthermore, it presents the most recent news updates and press releases on drugs targeting Substance Use Disorder.

Marketed Drugs

VIVITROL (naltrexone): Alkermes

VIVITROL developed by Alkermes, is a prescription medication used for the treatment of OUD and alcohol dependence. It is an opioid receptor antagonist that works by blocking the effects of opioids in the brain, which helps to reduce cravings and prevent the rewarding effects of opioid use. This action is particularly beneficial in preventing relapse and supporting patients in maintaining abstinence from opioids and alcohol. VIVITROL is administered as an intramuscular injection, providing a convenient once-monthly dosing regimen. VIVITROL was approved in the US in 2006.

In August 2023, Alkermes announced a settlement with Teva regarding patent litigation, granting Teva a license to market a generic version of VIVITROL in the US starting January 15, 2027, or earlier under certain conditions.

BRIXADI (buprenorphine): Braeburn

BRIXADI is an extended-release formulation of buprenorphine developed by Braeburn, approved in May 2023 by US FDA, administered via subcutaneous injection. It functions as a partial agonist at the mu-opioid receptor, providing a controlled modulation of opioid effects, which helps manage cravings and withdrawal symptoms in OUD. As a small molecule, BRIXADI is designed to penetrate cell membranes effectively and offer a long-lasting therapeutic effect. The subcutaneous injection route allows for sustained, steady release of the drug, enhancing patient compliance and supporting consistent treatment outcomes in the management of opioid dependence.

In June 2024, Braeburn, announced the publication of a post hoc analysis in JAMA Network Open, evaluating data from the Phase III trial comparing BRIXADI (buprenorphine) extended-release injection to daily sublingual buprenorphine/naloxone in patients with moderate to severe OUD, including those with fentanyl use.

Emerging Therapies

Mavoglurant (STP7/AFQ056): STALICLA

STP7 (mavoglurant) is a selective nonallosteric mGluR5 antagonist. mGluR5 has been tied to mood disorders, addiction, and rare and common forms of autism. The product is believed to block a certain protein in the brain, which research has shown is related to people's craving to use drugs like cocaine. A clinical Phase II study showed mavoglurant-induced abstinence in CUD patients through inhibition of mGluR5, with no evidence of withdrawal liability. The company plans to advance mavoglurant into Phase III development to treat CUD, which will be covered by the US National Institute on Drug Abuse (NIDA). Also, the company will use its precision neurobiology Drug Development Platform (DEPI) to detect subgroups of high-responder patients with rare and common neurodevelopmental disorders where mavoglurant can be an effective treatment, as guided by earlier clinical studies.

In May 2024, STALICLA announced the First Patient First Visit (FPFV) for the company's Drug-drug Interaction (DDI) study of STP7 (Mavoglurant), licensed to STALICLA by Novartis. The DDI study is the last regulatory requirement in a comprehensive Phase II program, and completion is expected to trigger the initiation of a Phase III study in the US in 2025.

BPL-003 (Mebufotenin): Atai Life Sciences/ Beckley Psytech

BPL-003, developed by Beckley Psytech, is an innovative therapeutic designed for the treatment of AUD. It belongs to a class of small molecules and is primarily categorized under antidepressants, mood stabilizers, and tryptamines. The product acts as a serotonin receptor modulator, targeting specific receptors in the brain to potentially influence mood regulation and reduce alcohol cravings. Administered intranasally, BPL-003 offers a non-invasive and efficient delivery route, enabling rapid absorption and a quick onset of action. The product is being developed to address AUD, utilizing its mechanism of action to modulate serotonin pathways, which are crucial in regulating mood and behavior, ultimately aiding in alcohol cessation and recovery. Currently, it is in Phase II of development for the treatment of AUD.

In April 2024, atai Life Sciences announced the publication of Beckley Psytech's Phase I study of BPL-003 in the Journal of Psychopharmacology. This publication highlights key findings on the safety, tolerability, and pharmacokinetic profile of BPL-003, an investigational treatment for AUD.

Substance Use Disorder (SUD) Market Outlook

The treatment landscape for SUD has advanced significantly with the approval of several medications, including VIVITROL (naltrexone), SUBLOCADE (extended-release formulation of naltrexone), and others, which help manage addiction by blocking opioid receptors and reducing cravings. These drugs play a critical role in supporting recovery. In addition to established therapies, emerging drug combinations such as gabapentin + nabilone and cyproheptadine + prazosin show promise for further improving SUD treatment. These combinations target various pathways involved in addiction, aiming to reduce cravings, manage withdrawal symptoms, and prevent relapse. As research progresses, these novel therapies may offer more personalized and effective treatment options, particularly for patients who have not responded well to traditional pharmacotherapies. The market for SUD treatment is expected to grow as new molecules and combination therapies are developed, paving the way for more successful interventions.

In summary, numerous therapies have already been approved for the management of SUD, with several effective medications currently available. While ongoing research continues to explore new treatments, many approved therapies are already making a significant impact in the SUD treatment landscape. The forecast period (2024-2034) is expected to bring further advancements, with emerging therapies enhancing existing treatment options. As healthcare spending continues to increase worldwide, the SUD treatment space is anticipated to see a positive shift, with more accessible and effective therapies becoming available to patients in need.

Substance Use Disorder (SUD) Disease Understanding and Treatment

Substance Use Disorder (SUD) Overview

Substance Use Disorder (SUD) is a complex condition marked by the uncontrolled use of substances, such as alcohol, tobacco, or other psychoactive drugs, despite harmful consequences. Individuals with SUD often become addicted, developing an intense focus on using these substances to the point where their daily functioning is impaired. Continued use leads to changes in brain function, particularly in areas related to judgment, decision-making, and behavioral control. These changes can cause cravings, distorted thinking, and behavioral shifts, even long after the immediate effects of intoxication wear off. Tolerance can develop, requiring larger amounts of the substance to achieve the desired effect, and withdrawal symptoms, including anxiety, may occur when use is discontinued.

Substance Use Disorder (SUD) Diagnosis

The diagnosis of Substance Use Disorder (SUD) begins with a comprehensive evaluation by a healthcare professional, often initiated by concerns raised by family members, friends, or the individual themselves. The process typically involves an intake assessment, which may occur at a drug rehab facility or through a physician or addiction specialist. The clinician will ask about the frequency of substance use, its impact on the person's life, and whether it has caused problems in social, occupational, or educational functioning. They will also assess whether physical dependence, withdrawal symptoms, and tolerance are present. Using the criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), the physician evaluates whether the individual meets at least two of the 11 diagnostic criteria for SUD within a one-year period. Based on the number of criteria met, the severity of the disorder is classified as mild (2-3 criteria), moderate (4-5), or severe (6 or more). This diagnostic evaluation helps determine the extent of the disorder and guides the treatment recommendations.

Substance Use Disorder (SUD) Treatment

Treatment for substance use disorder typically involves a combination of individual, group, and family therapy to develop skills for sobriety and navigate situations without turning to substances. Common therapeutic approaches include Cognitive Behavioral Therapy (CBT) to address negative thought patterns, Contingency Management (CM) to encourage sobriety with rewards, Motivational Interviewing (MI) to resolve ambivalence, and Dialectical Behavioral Therapy (DBT) to regulate emotions and reduce cravings. Other methods like Eye Movement Desensitization and Reprocessing (EMDR) for trauma, Rational Emotive Behavior Therapy (REBT) for healthier thinking, and Seeking Safety for trauma and substance misuse are also used. The Matrix Model, 12-Step Facilitation, and the Gottman Method for couples are additional strategies to promote recovery and prevent relapse. In addition to these therapies, medications such as buprenorphine, naltrexone and others are commonly used to treat substance use disorders, especially in managing opioid dependence.

Further details related to treatment and management are provided in the report...

Substance Use Disorder (SUD) Epidemiology

The Substance Use Disorder epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of SUD, Substance type-specific Cases of SUD, Total Treated Cases of SUD in the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2020 to 2034.

• Among the 7MM, the United States accounted for the highest number of cases of substance use disorder in 2023, with nearly 65 million cases. These cases are anticipated to increase by 2034.
• In 2023, the US recorded the highest prevalence of Tobacco use disorder, with ~26 million cases, followed by Cannabis use disorder, which accounted for ~19 million cases. These cases are expected to increase by 2034.
• In the 7MM, the United Kingdom accounted for the least number of treated cases of SUD in 2023, with approximately USD 1.17 million cases.
• Among the EU4 and the UK, France accounted for approximately USD 16.2 million diagnosed prevalent cases in 2023, the highest, while the United Kingdom accounted for approximately USD 8.2 million, the least.

KOL Views

To stay abreast of the latest trends in the market, we conduct primary research by seeking the opinions of Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) who work in the relevant field. This helps us fill any gaps in data and validate our secondary research.

We have reached out to industry experts to gather insights on various aspects of Substance Use Disorder, including the evolving treatment landscape, patients' reliance on conventional therapies, their acceptance of therapy switching, drug uptake, and challenges related to accessibility. The experts we contacted included medical/scientific writers, professors, and researchers from prestigious universities in the US, Europe, the UK, and Japan.

Our team of analysts at Delveinsight connected with more than 15 KOLs across the 7MM. We contacted institutions. By obtaining the opinions of these experts, we gained a better understanding of the current and emerging treatment patterns in the Substance Use Disorder market, which will assist our clients in analyzing the overall epidemiology and market scenario.

Qualitative Analysis

We perform Qualitative and Market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, designation, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in trials for Substance Use Disorder, one of the most important primary endpoints was achieving Change in anxiety as measured by heart rate, Change in blood pressure and anxiety, and others. Based on these, the overall efficacy is evaluated.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Because newly authorized drugs are often expensive, some patients escape receiving proper treatment or use off-label, less expensive prescriptions. Reimbursement plays a critical role in how innovative treatments can enter the market. The cost of the medicine, compared to the benefit it provides to patients who are being treated, sometimes determines whether or not it will be reimbursed. Regulatory status, target population size, the setting of treatment, unmet needs, the number of incremental benefit claims, and prices can all affect market access and reimbursement possibilities.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Substance Use Disorder (SUD) Report Insights

• Patient Population
• Therapeutic Approaches
• Substance Use Disorder Market Size and Trends
• Existing Market Opportunity

Substance Use Disorder (SUD) Report Key Strengths

• Eleven-year Forecast
• The 7MM Coverage
• Substance Use Disorder Epidemiology Segmentation
• Key Cross Competition

Substance Use Disorder (SUD) Report Assessment

• Current Treatment Practices
• Reimbursements
• Market Attractiveness
• Qualitative Analysis (SWOT, Conjoint Analysis, Unmet needs)

Key Questions:

• Would there be any changes observed in the current treatment approach?
• Will there be any improvements in Substance Use Disorder management recommendations?
• Would research and development advances pave the way for future tests and therapies for Substance Use Disorder?
• Would the diagnostic testing space experience a significant impact and lead to a positive shift in the treatment landscape of Substance Use Disorder?
• What kind of uptake will the new therapies witness in the coming years in Substance Use Disorder patients?

Table of Contents

1. Key Insights

2. Report Introduction

3. SUD Market Overview at a Glance

• 3.1. Market Share (%) Distribution of SUD in 2023 in the 7MM
• 3.2. Market Share (%) Distribution of SUD in 2034 in the 7MM

4. Methodology

5. Executive Summary

6. Key Events

7. Disease Background and Overview

• 7.1. Symptoms of SUD
• 7.2. Stages of Addiction Cycle
• 7.3. Types of SUDs
  • 7.3.1. Alcohol Use Disorder
  • 7.3.2. Cannabis Use Disorder
  • 7.3.3. Phencyclidine Use Disorder
  • 7.3.4. Other Hallucinogen-use Disorder
  • 7.3.5. Inhalant Use Disorder
  • 7.3.6. Opioid Use Disorder
  • 7.3.7. Sedative, Hypnotic, or Anxiolytic use disorder
  • 7.3.8. Stimulant use disorder
• 7.4. Risk Factors
• 7.5. Quality of Life in SUD
  • 7.5.1. General Impact on Quality of Life
  • 7.5.2. Mental Health Comorbidities
  • 7.5.3. Domain-specific Findings
  • 7.5.4. Predictors of Quality of Life
  • 7.5.5. Intervention Needs
• 7.6. Pathogenesis
  • 7.6.1. Genetic Influences
  • 7.6.2. Neurobiological Mechanisms
  • 7.6.3. Environmental Factors
  • 7.6.4. Psychiatric Comorbidities
• 7.7. Diagnosis of SUD
  • 7.7.1. Biomarkers in SUD
  • 7.7.2. Diagnostic Guidelines
  • 7.7.3. Differential Diagnosis

8. Treatment and Management of SUD

• 8.1. Types of Therapies Used
  • 8.1.1. Behavioral Therapy
  • 8.1.2. Family Therapy
  • 8.1.3. Individual Counselling
  • 8.1.4. Group Therapy
• 8.2. Principles of Effective Drug Addiction Treatment
• 8.3. Treatment Algorithm
  • 8.3.1. Treatment Guidelines
    • 8.3.1.1. VA/DoD Clinical Practice Guideline for The Management of SUD
    • 8.3.1.2. International Standards for the Treatment of SUD (WHO Recommendations)
    • 8.3.1.3. APA Clinical Practice Guidelines for SUD

9. Epidemiology and Patient Population

• 9.1. Key Findings
• 9.2. Assumptions and Rationale: The 7MM
  • 9.2.1. Diagnosed Prevalent Cases of CUD
  • 9.2.2. Diagnosed Prevalent Cases of OUD
  • 9.2.3. Diagnosed Prevalent Cases of AUD
  • 9.2.4. Diagnosed Prevalent Cases of Cannabis Use Disorder
  • 9.2.5. Diagnosed Prevalent Cases of Tobacco Use Disorder
• 9.3. Total Diagnosed Prevalent Cases of SUD in 7MM
• 9.4. Total Treated Cases of SUD in 7MM
• 9.5. The United States
  • 9.5.1. Total Diagnosed Prevalent Cases of SUD in the United States
  • 9.5.2. Substance type-specific Cases of SUD in the United States
  • 9.5.3. Treated Cases of SUD in the United States
• 9.6. EU4 and the UK
  • 9.6.1. Total Diagnosed Prevalent Cases of SUD in EU4 and the UK
  • 9.6.2. Substance type-specific Cases of SUD in EU4 and the UK
  • 9.6.3. Total Treated Cases of SUD in EU4 and the UK
• 9.7. Japan
  • 9.7.1. Total Diagnosed Prevalent Cases of SUD in Japan
  • 9.7.2. Substance type-specific Cases of SUD in Japan
  • 9.7.3. Treated Cases of SUD in Japan

10. Patient Journey

11. Marketed Therapies

• 11.1. Key Cross Competition
• 11.2. VIVITROL (naltrexone): Alkermes
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Clinical Development
  • 11.2.5. Safety and Efficacy
• 11.3. SUBLOCADE (buprenorphine): Indivior
  • 11.3.1. Product Description
  • 11.3.2. Regulatory Milestones
  • 11.3.3. Other Developmental Activities
  • 11.3.4. Clinical Development
  • 11.3.5. Safety and Efficacy
• 11.4. BRIXADI / BUVIDAL (buprenorphine): Braeburn
  • 11.4.1. Product Description
  • 11.4.2. Regulatory Milestones
  • 11.4.3. Other Developmental Activities
  • 11.4.4. Clinical Development
  • 11.4.5. Safety and Efficacy
• 11.5. SELINCRO (nalmefene): Lundbeck/Otsuka Pharmaceuticals
  • 11.5.1. Product Description
  • 11.5.2. Regulatory Milestone
  • 11.5.3. Other Development Activities
  • 11.5.4. Clinical Development
  • 11.5.5. Safety and Efficacy

12. Emerging Therapies

• 12.1. Key Cross Competition
• 12.2. IGALMI (Dexmedetomidine): BioXcel Therapeutics
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Developmental Activities
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Analyst View
• 12.3. NFL-101: NFL Biosciences
  • 12.3.1. Product Description
  • 12.3.2. Other Developmental Activities
  • 12.3.3. Clinical Developmental Activities
  • 12.3.4. Safety and Efficacy
  • 12.3.5. Analyst View
• 12.4. Mavoglurant (STP7/AFQ056): STALICLA
  • 12.4.1. Product Description
  • 12.4.2. Other Developmental Activities
  • 12.4.3. Clinical Developmental Activities
  • 12.4.4. Safety and Efficacy
  • 12.4.5. Analyst View
• 12.5. EMB-001: Embera NeuroTherapeutics
  • 12.5.1. Product Description
  • 12.5.2. Other Developmental Activities
  • 12.5.3. Clinical Developmental Activities
  • 12.5.4. Safety and Efficacy
  • 12.5.5. Analyst View
• 12.6. PP-01 (Gabapentin + nabilone): PleoPharma
  • 12.6.1. Product Description
  • 12.6.2. Other Developmental Activities
  • 12.6.3. Clinical Developmental Activities
  • 12.6.4. Safety and Efficacy
  • 12.6.5. Analyst View
• 12.7. KT-110 (Cyproheptadine + Prazosin): Kinnov Therapeutics
  • 12.7.1. Product Description
  • 12.7.2. Other Developmental Activities
  • 12.7.3. Clinical Developmental Activities
  • 12.7.4. Safety and Efficacy
  • 12.7.5. Analyst View
• 12.8. Sunobinop: Imbrium Therapeutics
  • 12.8.1. Product Description
  • 12.8.2. Other Developmental Activities
  • 12.8.3. Clinical Developmental Activities
  • 12.8.4. Safety and Efficacy
  • 12.8.5. Analyst View
• 12.9. BPL-003 (Mebufotenin): Atai Life Sciences/ Beckley Psytech
  • 12.9.1. Product Description
  • 12.9.2. Other Developmental Activities
  • 12.9.3. Clinical Developmental Activities
  • 12.9.4. Safety and Efficacy
  • 12.9.5. Analyst View

13. Substance Use Disorder (SUD): 7 Major Market Analysis

• 13.1. Key Findings
• 13.2. Market Outlook
• 13.3. Conjoint Analysis
• 13.4. Key Market Forecast Assumptions
• 13.5. Substance Use Disorder (SUD): 7 Major Market Analysis
  • 13.5.1. Total Market Size of SUD in the 7MM
  • 13.5.2. Total Market Size of SUD by Therapies in the 7MM
• 13.6. United States Market Size
  • 13.6.1. Total Market Size of SUD in the US (2020-2034)
  • 13.6.2. Market Size of SUD by Therapies in the United States (2020-2034)
• 13.7. EU4 and the UK Market Size
  • 13.7.1. Total Market Size of SUD in EU4 and the UK (2020-2034)
  • 13.7.2. Market Size of SUD by Therapies in EU4 and the UK (2020-2034)
• 13.8. Japan Market Size
  • 13.8.1. Total Market Size of SUD in Japan (2020-2034)
  • 13.8.2. Market Size of SUD by Therapies

14. KOL Views

15. SWOT Analysis

16. Unmet Needs

17. Market Access and Reimbursement

• 17.1. United States
• 17.2. Europe
• 17.3. Japan

18. Appendix

• 18.1. Bibliography
• 18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer